Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2023-01-20 Regulatory Filings
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the receipt of the Establishment Inspection Report (EIR) from the USFDA following a Pre-Approval Inspection. The document is brief (1245 characters) and serves as an announcement or update rather than a detailed report containing financial data or comprehensive analysis. It does not contain financial statements, management discussion, or detailed audit information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-20 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming no dematerialization requests for the quarter ended December 31, 2022. It is addressed to stock exchanges and regulatory bodies, and is a compliance certificate rather than a financial report or announcement of financial results. The document length is short (1643 characters) and it serves as a regulatory attestation. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not a full report or announcement of financial results.
2023-01-07 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the closure of the trading window pursuant to SEBI (Prohibition of Insider Trading) Regulations. It announces the trading window closure period related to the upcoming declaration of un-audited financial results for the quarter and nine months ended December 31, 2022. The document does not contain any financial data or results itself, nor does it present a report or detailed financial information. It is an announcement related to compliance and trading restrictions ahead of financial results disclosure. The document length is short (1265 characters), and it serves as a regulatory announcement rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2022-12-31 English
Updates
Regulatory Filings Classification · 100% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It reports an incident (a flash fire) at a manufacturing plant, including operational impact and employee casualties. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of management or board changes. The document is a regulatory announcement about a material event affecting the company. It fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2022-12-27 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the allotment of equity shares on exercise of Employee Stock Options (ESOPs) under two schemes (2016 and 2018). It details the number of shares allotted, exercise prices, premium, and total paid-up capital after allotment. The document references compliance with SEBI regulations related to share-based employee benefits and provides detailed annexures with share issuance data. There are no financial statements, earnings data, or management discussion. The document is an announcement of a capital change event (allotment of shares due to ESOP exercise). Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is about 5815 characters, which is sufficient for a detailed announcement rather than a brief notice. Hence, the classification is SHA with high confidence.
2022-12-17 English
Agreements/Contracts/Arrangements/ MOU's PARA B
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure submitted to stock exchanges (BSE and NSE) under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces a share subscription agreement and shareholders' agreement entered into by the company for subscribing equity shares in another company. The document details the shareholding, purpose, terms, and other disclosures related to this transaction. It is not a full financial report, audit, or earnings release, but rather an update on a capital transaction involving share subscription. The document length is under 5,000 characters and it is a regulatory disclosure about a financing/capital transaction. Therefore, it fits best under Capital/Financing Update (CAP).
2022-11-24 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.